StudyFinder
MTT for H.S. Investigate whether restoring normal gut microbiome composition with cMTT influences the relative overabundance of anaerobic bacteria and microbial diversity of the skin in patients with HS
Status: Recruiting
This research is being done to gain a better understanding of Hidradenitis Suppurativa (HS) and treatment with oral capsule microbiota transplant therapy (MTT) and the effects. Participants will be randomized (by chance) into 1 of 2 groups, treatment or placebo (no active ingredients) group. This study will last for up to 6 months
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• at least 18 years old
• diagnosis of Hidradenitis Suppurativa (HS)
• able to speak English
• women who are of child bearing age must use a highly effective form of birth control
• must be on a stable dose of medications for at least 30 days before starting the study
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:
• planning on moving within 6 months from start of study
• history of anaphylactic food allergies
• women who are pregnant, breastfeeding or planning to get pregnant during the time of the study
• history of inflammatory bowel disease or extensive bowel surgery
• see link to clinicaltrials.gov for complete exclusion criteria
Interventions:
Drug: Fecal Microbiota - lyophilized, Drug: Placebo drug
Conditions:
Dermatology (Skin, Hair & Nails)
Keywords:
Hidradenitis Suppurativa, HS
Study Contact: Thomas Pritchard - pritc204@umn.edu
Principal Investigator: Noah Goldfarb
Phase: EARLY_PHASE1
IRB Number: STUDY00018878
See this study on ClinicalTrials.gov